[ XXXX in Iceland 2000-2009: Incidence and survival].

@entity1 @entity66 @entity5 @entity72697 @entity189 @entity4797
INTRODUCTION: Survival of @entity1 with testicular germ cell @entity5 has improved in recent years, mainly due to new modes of chemotherapy. We analyzed incidence, staging and survival of @entity1 diagnosed during the last ten years in Iceland and compared the results to previous studies. MATERIALS AND METHODS: A retrospective study including all Icelandic males diagnosed during 2000-2009. Pathology reports were reviewed and the @entity5 staged (Boden-Gibb). Overall survival was estimated and @entity4797 (ST) and @entity4797 ( @entity72697 ) compared. RESULTS: 97 males were diagnosed, age-adjusted incidence being 5.9/100.000 males per year. The number of ST and @entity72697 was almost equal, and the mean age was 35.6 (range; 15-36), but @entity1 with ST were 11.5 years older compared to @entity72697 . Symptoms were similar in both groups, also @entity5 size (4.0 cm), which did not change during the study period. Most of the @entity5 were in stage I, or 78.4%, 13.4% were in stage II og 8.2% in stage III-IV. ST were diagnosed at a significantly lower stage compared to @entity72697 (91.7 versus 65.3% in stage I; p=0.003). No distant metastases were diagnosed in @entity1 with ST but in 8 @entity1 with @entity72697 . Four @entity1 died during the study period, two due to @entity72697 but no @entity1 died because of ST. Five-year survival for the whole @entity1 group was 95.1%. CONCLUSION: The incidence of @entity189 in Iceland is similar to neighbouring countries and has remained fairly constant for the last two decades. At the same time the number of @entity1 with @entity66 (stage I) as well as the size of the @entity5 has not changed significantly. Survival in Iceland is comparable to the best results reported elsewhere.
